BibTex format

author = {Elliott, P and Haw, D and Wang, H and Eales, O and Walters, C and Ainslie, K and Atchison, C and Fronterre, C and Diggle, P and Page, A and Trotter, A and Prosolek, S and The, COVID-19 Genomics UK Consortium COG-UK and Ashby, D and Donnelly, C and Barclay, W and Taylor, G and Cooke, G and Ward, H and Darzi, A and Riley, S},
doi = {10.1126/science.abl9551},
journal = {Science},
pages = {1--11},
title = {Exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with Delta variant},
url = {},
volume = {374},
year = {2021}

RIS format (EndNote, RefMan)

AB - SARS-CoV-2 infections were rising during early summer 2021 in many countries associated with the Delta variant. We assessed RT-PCR swab-positivity in the REal-time Assessment of Community Transmission-1 (REACT-1) study in England. We observed sustained exponential growth with average doubling time (June-July 2021) of 25 days driven by complete replacement of Alpha variant by Delta, and by high prevalence at younger less-vaccinated ages. Unvaccinated people were three times more likely than double-vaccinated people to test positive. However, after adjusting for age and other variables, vaccine effectiveness for double-vaccinated people was estimated at between ~50% and ~60% during this period in England. Increased social mixing in the presence of Delta had the potential to generate sustained growth in infections, even at high levels of vaccination.
AU - Elliott,P
AU - Haw,D
AU - Wang,H
AU - Eales,O
AU - Walters,C
AU - Ainslie,K
AU - Atchison,C
AU - Fronterre,C
AU - Diggle,P
AU - Page,A
AU - Trotter,A
AU - Prosolek,S
AU - The,COVID-19 Genomics UK Consortium COG-UK
AU - Ashby,D
AU - Donnelly,C
AU - Barclay,W
AU - Taylor,G
AU - Cooke,G
AU - Ward,H
AU - Darzi,A
AU - Riley,S
DO - 10.1126/science.abl9551
EP - 11
PY - 2021///
SN - 0036-8075
SP - 1
TI - Exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with Delta variant
T2 - Science
UR -
UR -
UR -
VL - 374
ER -

Other publications